Cure of human ovarian carcinoma solid xenografts by fractionated [211At] alpha-radioimmunotherapy: Influence of tumor absorbed dose and effect on long-term survival

Keyphrases

• Tumor 100%
• Long-term Survival 100%
• Radioimmunotherapy 100%
• 211At 100%
• Xenograft 100%
• Tumor Absorbed Dose 100%
• Human Ovarian Carcinoma 100%
• Tumor Growth 75%
• Complete Remission 50%
• Hematocrit 50%
• Dose Level 50%
• Activity Groups 50%
• MX35 50%
• Myelotoxicity 50%
• Absorbed Dose 50%
• Micrometastatic Disease 50%
• Targeted alpha Therapy 50%
• Bone Marrow Recovery 50%
• Low Activity 25%
• Poor Health 25%
• High Activity 25%
• Dose Effect 25%
• Median Survival 25%
• Biological Effects 25%
• Subcutaneous Tumor 25%
• OVCAR-3 25%
• Activity Level 25%
• Reduced Body 25%
• Solid Tumors 25%
• Therapy Regimen 25%
• Dehydration 25%
• Minimal Change Disease 25%
• Injected Activity 25%
• Tumor Xenograft 25%
• Biodistribution 25%
• Tumor Eradication 25%
• Administered Activity 25%
• Long-term Toxicity 25%
• Subcutaneous Tumor Model 25%
• Toxicity Effects 25%
• Toxicity Analysis 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Ovary Carcinoma 100%
• Neoplasm 100%
• Long Term Survival 100%
• Tumor Growth 42%
• Disease 28%
• Mouse 28%
• Remission 28%
• Bone Marrow Toxicity 28%
• Tumor Model 14%
• Solid Malignant Neoplasm 14%
• Biodistribution 14%